Please ensure Javascript is enabled for purposes of website accessibility

Chemours Company: Bulls Need a Reality Check

By Maxx Chatsko - Nov 30, 2017 at 9:19AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors need to take the unfolding public health worries in North Carolina more seriously.

Two catalysts have led to 129% gains for specialty chemical manufacturer Chemours Co. (CC 0.43%) in the past year. The long-awaited recovery in selling prices of titanium dioxide, for which the company is the leading global manufacturer, has provided one continuous boost throughout 2017.

But the catalyst that started the stock rally occurred in February 2017, when the company settled a drawn-out legal fight concerning the dumping of a toxic chemical into public waterways. The $670 million settlement removed a cloud of uncertainty that had been hanging over the stock -- and on terms that were more favorable than the worst-case scenario Wall Street envisioned. Better yet, since Chemours had stopped using the toxic chemical in its American manufacturing processes, many assumed related liabilities were a thing of the past.

An unfolding environmental and public health issue in Fayetteville, North Carolina, could prove otherwise. It may be the reality check Chemours bulls need to consider that profits aren't the only bottom line to consider for an investment.

A goldfish jumping from a dirty water bowl to a clean one.

Image source: Getty Images.

Business is booming, but uncertainty looms

Chemours reports financial performance in three business segments, which have performed as follows in the first nine months of 2016 and 2017: 


First Nine Months, 2016

First Nine Months, 2017

% Change

Titanium technologies, revenue

$1.74 billion

$2.17 billion


Titanium technologies, adjusted EBITDA

$309 million

$601 million


Fluoroproducts, revenue

$1.69 billion

$1.99 billion


Fluoroproducts, adjusted EBITDA

$333 million

$510 million


Chemical solutions, revenue

$641 million

$437 million


Chemical solutions, adjusted EBITDA

$30 million

$37 million


Data source: SEC filings.

Business has been booming in 2017 thanks to price increases in the two largest segments: titanium technologies and fluoroproducts. The former is comprised of sales of titanium dioxide, a nanoparticle with myriad uses as a pigment in paints, sunscreens, and foods. The latter consists of sales of products that include fuel cell membranes, refrigerants, and nonstick coatings (with Teflon being the most famous). While useful to modern life, fluoroproducts have one crucial drawback: the manufacturing process.

That's because the chemical reaction used to produce fluoroproducts requires a class of processing aids that are incredibly toxic to human health. The settlement announced in February 2017 concerned the environmental release of the processing aid PFOA, which was phased out years ago. Chemours replaced it with a processing aid known as GenX, which, unfortunately, appears to be similarly toxic.

This wasn't exactly a surprise. The U.S. Environmental Protection Agency raised issues with GenX prior to its industrial use, but a lax regulatory system for chemical safety meant the concerns were nothing more than words on a piece of paper. Chemours proceeded unimpeded, although the state of North Carolina may soon erect the first serious roadblock.

North Carolina is getting serious

Chemours owns a manufacturing facility in Fayetteville, North Carolina that used to manufacture PFOA and now manufactures GenX. It's at the center of unfolding public health concerns. Why? The state of North Carolina has legal limits for the concentration of the processing aids allowed in drinking water. However, tests conducted throughout the year have detected worrisome levels of PFOA and GenX in Cape Fear River and related waterways, where the discharged industrial water ends up.

A few notes and developments of relevance to investors:  

  • Chemours no longer uses PFOA in the United States. It doesn't break down in the environment, which means recently detected amounts are likely legacy pollution from years past.
  • In June 2017, the company committed to stop discharging GenX into local waterways around its Fayetteville facility. However, as recently as October, state officials detected levels of GenX coming out of the chemical complex's discharged water that were up to 26 times higher than the legal threshold for drinking water. The discharge doesn't actually become drinking water, but the company is supposed to alert regulators of discharge events of that magnitude, and it didn't. 
  • After the October tests, environmental regulators moved to revoke the company's ability to discharge wastewater from the site and referred the incidents to the North Carolina Bureau of Investigation for potential criminal charges. 
  • In the company's latest 10-Q, it noted five separate lawsuits filed against it for its actions in Fayetteville including from residents, the Cape Fear Public Utility Authority, and nearby Brunswick County. 
  • The state continues to expand its sampling of residential wells near the facility. At last count, 85 households were being supplied with bottled water due to GenX levels in their wells being above the provisional state health goal. 

It's still possible that the company will avoid potential fines or costly legal battles, but recent events certainly aren't favorable to the company. Consider that the households being supplied with bottled water (courtesy of Chemours, as ordered by the state) will need to dig deeper wells or be connected to the local water system with new and costly water lines. That could take months or years.

Or consider that the company's former parent, Dow Chemical, now part of DowDuPont, may disagree with its liability in any potential lawsuits. A similar dispute elevated Wall Street's concern over the settlement involving PFOA that was announced earlier this year. Each company paid half of the $670 million settlement, easing concerns, but that may not be the case for lawsuits over GenX.

No matter how this plays out, one thing is sure: Uncertainty is about to return for Chemours. And uncertainty is never good for a stock.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

The Chemours Company Stock Quote
The Chemours Company
$30.22 (0.43%) $0.13

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.